Upcoming Event: ESGCT 2026 x KACTUS

We are excited to share that KACTUS will be at the 33rd ESGCT Annual Congress, taking place October 27-30, 2026 at the Congress Center Hamburg in Hamburg, Germany. Held in collaboration with the German Society for Gene Therapy (DG-GT), ESGCT brings together scientists, clinicians, and industry leaders from around the world to exchange knowledge and advance the fields of gene and cell therapy.

What is ESGCT?

The European Society of Gene & Cell Therapy is a professional society dedicated to promoting basic and clinical research in gene therapy, cell therapy, and genetic vaccines. Through education, scientific exchange, and collaboration, ESGCT connects researchers across academia and industry while also serving as a professional adviser to stakeholder communities and regulatory bodies throughout Europe.

The ESGCT Annual Congress is the society’s flagship scientific meeting, bringing together the international gene and cell therapy community to highlight the latest research, technologies, and therapeutic advances. The four-day program features invited and selected presentations, educational sessions, clinical and commercialization workshops, poster sessions, symposia, an exhibition, and networking opportunities covering topics from gene editing and vector development to CAR T cells, manufacturing, disease models, and clinical translation.

Event Overview

Venue: Congress Center Hamburg (CCH), Congressplatz 1, 20355 Hamburg, Germany
Dates: October 27–30, 2026

Conference Day 1: Tuesday, October 27, 2026 8:30 AM–9:00 PM
- Exhibit Hall Hours: 10:30 AM–9:00 PM

Conference Day 2: Wednesday, October 28, 2026 8:00 AM–6:30 PM
- Exhibit Hall Hours: 9:00 AM–6:00 PM

Conference Day 3: Thursday, October 29, 2026 8:00 AM–7:00 PM
- Exhibit Hall Hours: 9:00 AM–6:00 PM

Conference Day 4: Friday, October 30, 2026 8:30 AM–5:00 PM
- Exhibit Hall Hours: 9:00 AM–3:00 PM

KACTUS Booth: D-04

Event Schedule

The 33rd ESGCT Annual Congress will run for four days, October 27–30, 2026, with educational programs, plenary and parallel scientific sessions, posters, workshops, symposia, and networking opportunities covering the latest advances in gene and cell therapy. For the most up-to-date daily schedule, including individual presentation details, please consult the live Full Programme on the ESGCT website.

Day 1: Tuesday, October 27, 2026

Education Sessions 1a and 1b: 9:00–10:45 AM
Clinical Trials and Commercialisation Workshop 1: 9:30–11:00 AM
Exhibit Hall open from 10:30 AM–9:00 PM
Education Coffee Break: 10:45–11:15 AM
Clinical Trials Coffee Break: 11:00–11:15 AM
Education Sessions 2a and 2b: 11:15 AM–1:00 PM
Clinical Trials and Commercialisation Workshop 2: 11:15 AM–1:00 PM
Session 1 – ESGCT 2026 Opening: 2:00–4:30 PM
Coffee Break: 4:30–5:00 PM
Parallel Sessions 2a–2d: 5:00–7:30 PM
Welcome Reception: 7:30–9:00 PM

Day 2: Wednesday, October 28, 2026

Registration: 8:00–8:30 AM
Parallel Sessions 3a–3d: 8:30–10:30 AM
Exhibit Hall open from 9:00 AM–6:00 PM
Coffee Break: 10:30–11:00 AM
Parallel Sessions 4a–4d: 11:00 AM–12:30 PM
Lunch: 12:30–1:30 PM
Symposium – AI and Machine Learning: 1:30–2:30 PM
Poster Session I: 1:30–3:30 PM
Session 5 – In Vivo Gene Therapy: 3:30–5:30 PM
Coffee Break: 5:30–6:00 PM
Session 6 – Gene Editing: 6:00–6:30 PM

Day 3: Thursday, October 29, 2026

Registration: 8:00–8:30 AM
Parallel Sessions 7a–7d: 8:30–10:30 AM
Exhibit Hall open from 9:00 AM–6:00 PM
Coffee Break: 10:30–11:00 AM
Session 8 – Presidential Symposium: 11:00 AM–1:00 PM
ESGCT AGM: 1:00–1:30 PM
Poster Session II: 2:00–4:00 PM
Parallel Sessions 9a–9d: 4:00–6:00 PM
Coffee Break: 6:00–6:30 PM
Session 10 – Enabling Technologies: 6:30–7:00 PM
Molecular Mingle: 8:00 PM

Day 4: Friday, October 30, 2026

Registration: 8:30–9:00 AM
Exhibit Hall open from 9:00 AM–3:00 PM
Parallel Sessions 11a–11d: 9:00–10:30 AM
Coffee Break: 10:30–11:00 AM
Parallel Sessions 12a–12d: 11:00 AM–1:00 PM
Lunch: 1:00–2:30 PM
Session 13 – Cancer Models & Gene Therapy: 2:30–4:45 PM
Concluding Remarks
Farewell Drinks: 4:45–5:00 PM

About KACTUS

KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 3,000 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.